IRF/Type I IFN signaling serves as a valuable therapeutic target in the pathogenesis of inflammatory bowel disease.
Int Immunopharmacol. 2021 Jan 11;92:107350. doi: 10.1016/j.intimp.2020.107350. Online ahead of print.
Int Immunopharmacol. 2021.
PMID: 33444921
Review.